Correspondence

PDF
Newsletter - January 2017 PDF 226Kb

Data Issue 2: Updates, amendment, dasatinib supply and causality assesment for AEs and SAEs

PDF
Newsletter - January 2017 supplementary PDF 72Kb

SAE completion guidelines, v2.0

PDF
Newsletter - September 2016 PDF 247Kb

Data - Issue 1 : End of Trial and SAEs

PDF
Newsletter - September 2016 supplementary PDF 334Kb

Visit 15 and early discontinuation eCRF completion guide

PDF
Newsletter - April 2016 PDF 44Kb

End of year three data, PI changes and trust mergers, Menorrhagia and CML Patient Day

PDF
Newsletter - July 2015 PDF 66Kb

Pleural effusion with dasatinib can occur late

PDF
Newsletter - February 2014 PDF 320Kb

Patient at 5 years (visit 15), dasatinib and site closure, CML patient meeting, eCRF con med entries and SPIRIT 2 slides from ASH

PDF
Newsletter - April 2013 PDF 269Kb

Recruitment success, Diagnostic kits, AEs, SAE reporting, CML proffesional Day and data queries

PDF
Newsletter - December 2012 PDF 330Kb

Christmas arrangements, CML meetings, Home deliveries of study drug and Lab toxicities and AEs

PDF
Newsletter - July 2012 PDF 349Kb

700th patient recruited, Dasatinib tablet strenghts, Common toxicity criteria, Imatinib labels and Sample boxes

PDF
Newsletter - November 2011 PDF 289Kb

500th patient milestone, Benefit beyond patients, Post treatment follow up, Monitoring visit findings, Christmas arrangements, Meetings, FAQs, Patient access and Website documentation.

PDF
Newsletter - March 2011 PDF 95Kb

370 patients recruited, eCRF training and Physical examinations

PDF
Newsletter - November 2010 PDF 263Kb

322 patients recruited, QoL patient labels, Patients coming off trial and Visit 7 bone marrow.

PDF
Newsletter - September 2010 PDF 534Kb

SPIRIT team and Data completeness.

PDF
SPIRIT 2 - End of Trial Schematic PDF 315Kb

SPIRIT 2 - End of Trial Schematic